SCHEMBL10293545

SCHEMBL10293545

CCCNc1ncc(Br)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CCNC P24863 1/20 0.41
HTT P42858 1/20 0.41
CDK8 P49336 1/20 0.41
ALDH1A1 P00352 2/20 0.39
ACACB O00763 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
HCAR3 P49019 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2068114 0.82 NPC1 (0.50) NPC1RAB9AHTTALDH1A1ACACB
SCHEMBL4687077 0.81 NPC1 (0.46) NPC1RAB9AHTTALDH1A1KMT2A
SCHEMBL10293497 0.80 ALDH1A1 (0.41) ALDH1A1ACACBCYP1A2CYP2C19KMT2A
SCHEMBL13662123 0.78 ACACB (0.40) ALDH1A1ACACBCYP1A2CYP2C19KMT2A
SCHEMBL9988637 0.78 NPC1 (0.43) NPC1RAB9AHTTALDH1A1KMT2A
SCHEMBL18637831 0.78 NR1I2 (0.45) NPC1RAB9AALDH1A1ACACBCYP1A2
SCHEMBL9960367 0.78 EGFR (0.44) NPC1RAB9ACYP2C19
SCHEMBL1256248 0.78 KCNH3 (0.44) NPC1RAB9AHTTALDH1A1ACACB
SCHEMBL13657985 0.75 KMT2A (0.40) RAB9AALDH1A1ACACBCYP1A2CYP2C19
SCHEMBL21513657 0.75 IGF1R (0.44) NPC1RAB9AKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114984003-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-08-27 CN disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
US-11524938-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-13 US disclosed
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US disclosed
CN-115054600-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-16 CN disclosed
CN-114984003-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-02 CN disclosed
EP-3763704-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2021-01-13 EP disclosed
US-10844016-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-11-24 US disclosed
EP-3458443-B1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma AG (DE) 2020-08-19 EP disclosed
WO-2020132004-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD SAINT LOUIS UNIVERSITY (US) 2020-06-25 WO disclosed
EP-3458443-A1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2019-03-27 EP disclosed
WO-2017191000-A9 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-12-27 WO disclosed
WO-2017191000-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-09 WO disclosed
US-8853420-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-07 US disclosed
US-8853420-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-07 US disclosed
EP-2471787-A1 New compounds Boehringer Ingelheim International GmbH (DE) 2012-07-04 EP disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 US disclosed
US-20110263565-A1 COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 US disclosed
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-10-21 US disclosed
WO-2010012747-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 NPC1 784/4885RAB9A 3177/4885CCNC 3210/4885
US-11524938-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 NPC1 784/4885RAB9A 3177/4885CCNC 3210/4885
US-10844016-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 NPC1 784/4885RAB9A 3177/4885CCNC 3210/4885
US-20110263565-A1 COMPOUNDS MKI67, CCNA1, CCNT1 NPC1 81/4885RAB9A 1014/4885CCNC 28/4885
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 NPC1 3/4885RAB9A 3451/4885CCNC 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.